Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Revvity agreed to acquire Human Cell Design to add EndoC-βH5 cells, reagents, services and NatLine cell-line technology, which it plans to integrate with its detection tools. UBS cut Revvity to Neutral and set a $140 price target.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.
Revvity plans to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery.